Camurus ABCAMRF -3.57%79 Altman Z-Score is 37.20 as of Jun. 24, 2026, which is 21% above its 10-year median of 30.81. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 935 Biotechnology companies, Camurus AB ranks better than 93.48% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 36.85 is strong.
Camurus AB has a Altman Z-Score of 37.20, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Camurus AB's Altman Z-Score or its related term are showing as below:
CAMRF'
s Altman Z-Score Range Over the Past 10 Years
Min: 9.53 Med: 30.81 Max: 51.66
Current: 36.85
During the past 13 years, Camurus AB's highest Altman Z-Score was 51.66. The lowest was 9.53. And the median was 30.81.
Camurus AB (OTCPK:CAMRF) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Camurus AB Altman Z-Score Related Terms
Camurus AB Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Camurus AB's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Camurus AB's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Camurus AB's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Camurus AB's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.8504
+
1.4
*
0.1521
+
3.3
*
0.1735
+
0.6
*
58.2479
+
1.0
*
0.4481
=
37.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Camurus AB (CAMRF) has a Altman Z-Score of 37.20 as of Jun. 24, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Camurus AB and its competitors. This is 21% above median its historical median of 30.81. Over the past decade, Camurus AB's Altman Z-Score has ranged from 9.53 to 51.66. According to the industry distribution chart, Camurus AB ranks #61 out of 935 companies in the Biotechnology industry, placing it in the top 6.5%.
Is Camurus AB's Altman Z-Score too high?
Camurus AB's current Altman Z-Score of 37.20 is 21% above median its 10-year median of 30.81. Over the past 10 years, this metric has ranged from a low of 9.53 to a high of 51.66. The Biotechnology industry median Altman Z-Score is 2.64. Camurus AB's value of 37.20 is 1309.1% above this industry median. Based on the distribution chart, Camurus AB ranks #61 out of 935 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #61 out of 935 companies for Altman Z-Score. This places Camurus AB in the top 7% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.64. Camurus AB's value of 37.20 is 1309.1% above this benchmark. Historically, Camurus AB's own Altman Z-Score has ranged from 9.53 to 51.66 over the past decade. While the company's 10-year median is 30.81 vs. the industry median of 2.64, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.64, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Altman Z-Score of 37.20 is 1309.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Altman Z-Score is 37.20, which is 21% above median its own 10-year median of 30.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.14, compared to a current price of $54.00 — trading 35% below its estimated fair value. The current Altman Z-Score is 37.20, which is 21% above median its 10-year median of 30.81 and 1309.1% above the Biotechnology industry median of 2.64. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Altman Z-Score is 37.20 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 35% below its estimated GF Value™ of $83.14.
GuruFocus considers Camurus AB to be Significantly Undervalued.
Key valuation signals for CAMRF:
Altman Z-Score: 37.20 (21% above median its 10-year median of 30.81)
GF Value™: $83.14 vs. price of $54.00 (35% below fair value)
Industry Position: 1309.1% above the Biotechnology median (#61 of 935)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score
Get the complete analysis for CAMRF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
